Please provide your email address to receive an email when new articles are posted on . A new drug application submitted to the FDA seeks approval of roflumilast foam 0.3% for adults and adolescents ...

Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases.

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved ...

Human scalp with dandruff, computer illustration. Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor. Positive topline results were announced from a phase 3 trial ...

It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United States If approved, roflumilast foam would be the first topical drug for seborrheic ...

Seborrheic dermatitis is a skin condition that may cause symptoms like patches of skin that are lighter than the surrounding areas (hypopigmentation) and curved lesions in people with dark skin.